Medindia

X

Dr Reddy's Laboratories To Buy IP Rights Of Anti-Coagulant Drug For $17.5M

by Shirley Johanna on  September 26, 2015 at 10:51 AM Drug News   - G J E 4
Australian drug discovery and development company Alchemia entered into a $17.5 million agreement with Dr Reddy's laboratories for exclusive intellectual property rights for anti-coagulant drug.
Dr Reddy's Laboratories To Buy IP Rights Of Anti-Coagulant Drug For $17.5M
Dr Reddy's Laboratories To Buy IP Rights Of Anti-Coagulant Drug For $17.5M
Advertisement

The sale is conditional on shareholder approval, as the sale constitutes a disposal of the company's main undertaking as per ASX listing rules, said the statement by Alchemia.

Advertisement
An anti-coagulant drug, fondaparinux sodium is generic version of Arixtra drug and has been approved by US and Europe for treating deep vein thrombosis and pulmonary embolism, it added.

Alchemia markets Fondaparinux in the US and other markets through partner Dr. Reddy Laboratories, the statement added.

Source: IANS
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All